molgramostim

YARDLEY, Pa., August 24, 2026 Savara Inc. will present new and previously reported Phase 3 IMPALA-2 clinical trial data...

ORLANDO, Fla., May 19, 2026 Savara presented new long-term efficacy and safety data from the ongoing IMPALA-2 Phase 3...

LANGHORNE, Pa., April 15, 2026 Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced that the...

Langhorne, Pennsylvania, USA, April 7, 2026 MHRA Acceptance Marks Key Regulatory Milestone In a significant advancement for rare disease...

LANGHORNE, Pa., November 2, 2025 — Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases,...